Benefits
Anxiety and stress reduction, one trial
One randomized placebo-controlled trial, in 97 adults reporting mild to moderate anxiety over 8 weeks, is the entire human evidence for this claim. Anxiety and stress scores fell in the placebo group as well; the fall was significantly greater on the extract on the GAD-7 anxiety scale and the Perceived Stress Scale at weeks 4 and 8. It has not been replicated, and the ingredient manufacturer part-funded the trial. This is the only evidence for the Calmaluma stress positioning, and it is separate from the older weight management research done under the Slimaluma brand. Salivary cortisol changed significantly in the male participants and not in the female ones, a split by sex rather than a whole-group result.
Salivary cortisol moved in the men only
In the one anxiety trial, salivary cortisol showed a statistically significant change in the male participants and no significant change in the female participants. The authors read this as a hint that the extract may act through the HPA axis, not as a demonstrated cortisol-lowering effect, and the analysis was a subgroup split rather than the trial's main outcome. Cortisol is the primary stress hormone, and sustained elevation contributes to anxiety, weight gain, sleep disturbance, and immune dysregulation. An independent 2022 systematic review of 52 human trials of single plants and phytonutrients, which included Caralluma fimbriata, concluded that for most of them the effect on stress hormone activity is unclear, with ashwagandha the one consistent exception. Treat this as a possible mechanism, not a proven one.
Appetite suppression and satiety
Appetite is the older use for this extract and the evidence is mixed. Two individual trials found lower hunger ratings and lower calorie intake at 1 g/day, but the 2021 pooled analysis of all 7 trials found no significant change in appetite measures and concluded the extract is unlikely to be recommended as an appetite suppressant. A trial of the same extract (Slimaluma brand) showed reductions in waist circumference and modest body composition changes at 1 g/day. Use as a famine food by Indian tribal communities is a tradition worth reporting, but it is not evidence that the extract suppresses appetite. This is eating research, not stress research, and it does not support the anxiety claims above.
Animal feeding studies only
Rodent studies of this extract report lower food intake and less weight gain, but no published study of it shows a shift toward less sugary food. One rat study of the same branded extract found hypothalamic neuropeptide Y and orexin went up rather than down, so the appetite pathway is not settled. Nothing here has been tested for human food choice, and none of it bears on stress or anxiety.
Waist circumference reduction (Slimaluma evidence)
Pooled analysis of Caralluma fimbriata trials documented significant waist circumference reduction (~1.6 cm) and waist-to-hip ratio improvement vs placebo, with no significant effects on body weight or BMI. Waist circumference is only a proxy for visceral fat, which was not measured directly, and the review authors concluded the extract is unlikely to be recommended as a weight loss supplement. This is weight research and says nothing about stress or anxiety.
Traditional Indian medicinal use
Indian tribal people have used Caralluma fimbriata for centuries — consumed as a vegetable during times of famine to suppress hunger and sustain energy during food scarcity. This traditional use supports the general safety profile and provides the historical rationale for modern appetite-suppression research with the standardized extract.
Stress and appetite are two separate evidence bases
The idea that one cortisol mechanism drives both the calming effect and the appetite effect is a supplier hypothesis, not a finding. No trial has tested stress eating, emotional eating or a combined stress and weight outcome with this extract, and the cortisol result it rests on was a single subgroup analysis. Read the two effects as separate and separately evidenced.
Mechanism of action
Pregnane glycoside bioactivity
Pregnane glycosides are the characterized bioactive class in Caralluma fimbriata. The exact molecular mechanism of appetite suppression by pregnane glycosides is unclear, but proposed mechanisms include modulation of hypothalamic NPY/AgRP signaling (the orexigenic appetite-stimulation pathway) and direct effects on ghrelin and leptin signaling.
HPA axis cortisol modulation
The one anxiety trial measured salivary cortisol, not serum cortisol, and found a significant change in men and none in women. The authors suggested this points to the hypothalamic-pituitary-adrenal (HPA) axis, which is a proposal rather than a demonstrated mechanism. Whether it explains the calming effect, or the separate appetite and waist findings, has not been tested.
Appetite hormone modulation
The foundational mechanism trial measured plasma satiety biomarkers including ghrelin (hunger hormone), leptin (satiety hormone), and neuropeptide Y (NPY — central appetite-stimulating peptide). Only leptin differed between groups: it rose in the placebo group and stayed flat on the extract. Ghrelin and neuropeptide Y showed no significant difference between groups, so the satiety mechanism is not established.
Anxiolytic mechanism (proposed)
The anxiolytic effect mechanism is not fully characterized but may involve cortisol reduction, GABAergic modulation, or central nervous system effects via the pregnane glycoside content. The neuroactive pregnane compounds usually cited, such as allopregnanolone, are neurosteroids the body makes and are not the same class of molecule as the plant pregnane glycosides in this extract, so that comparison is not evidence. The receptor level work on this extract amounts to a mouse study pointing at the 5-HT2c serotonin receptor, and it concerned food intake rather than anxiety.
Clinical trials
Randomized placebo-controlled clinical trial evaluating Caralluma fimbriata for anxiety and stress in healthy adults. 8-week intervention. Published in the Journal of Affective Disorders 2019;246:619-626 by Kell G, Rao A, Katsikitis M, PubMed ID 30609411. Cortisol biomarker tracking alongside validated psychological instruments.
97 adults self-reporting mild to moderate anxiety, 49 on the extract and 48 on placebo. This was not a clinically diagnosed anxiety population. 8-week intervention.
Caralluma fimbriata at 500 mg twice daily significantly reduced anxiety and stress scores vs placebo over 8 weeks. Anxiety and stress fell in the placebo group too; the extract group fell further on the GAD-7 and the Perceived Stress Scale. On the PANAS mood scale, negative affect improved more on the extract at week 4 but not at week 8, and positive affect improved more at week 8. Salivary cortisol changed significantly in the men and not in the women. The ingredient manufacturer part-funded the trial, and the result has not been independently replicated. This is the only published human trial of this extract on stress, anxiety or mood.
Randomized double-blind placebo-controlled trial in overweight Australian adults. 16-week intervention with 500 mg Caralluma fimbriata extract (Slimaluma) twice daily before meals. Published in Scientific Reports 2021;11(1):6791 by Rao A, Briskey D, Dos Reis C, Mallard AR, PubMed ID 33762661. Registered ACTRN12617000872336.
83 men and women aged 20-50 in Australia. 16-week intervention.
Caralluma fimbriata supplementation reduced calorie intake and waist circumference over 16 weeks. Body weight barely moved on the extract, a 0.37 kg loss against a 1.33 kg gain on placebo, and the authors described the result as maintaining body weight rather than reducing it. Of the three satiety biomarkers, only leptin differed between groups; ghrelin and neuropeptide Y did not. This trial measured appetite and body composition, and measured no stress, anxiety or mood outcome. Cardiometabolic biomarkers (lipid profile, glucose, insulin) also assessed. Effect on total body weight was modest; effects on waist circumference were more robust.
Evidence review and pooled analysis of 7 clinical trials of Caralluma fimbriata across populations in Australia, Cuba, India, and Spain. Published in BMC Complementary Medicine and Therapies 2021;21(1):279, PubMed ID 34758791. Pooled analysis of anthropometric, biochemical, and appetite parameters.
Pooled across 7 trials of mostly overweight/obese adults plus one trial in children with Prader-Willi syndrome.
Significant reduction in waist circumference (-1.59 cm) and waist-to-hip ratio (-0.06) vs placebo. No significant effects on body weight, BMI, or hip circumference. No significant effects on biochemical or appetite parameters in pooled analysis. The pooled analysis concluded Caralluma fimbriata is unlikely to be recommended as a weight loss supplement or an appetite suppressant. It did not examine stress, anxiety or mood at all, so it cannot be read as support for the Calmaluma positioning.